ADC Therapeutics SA

ADCT Healthcare Drug Manufacturers Specialty & Generic

ADC Therapeutics SA’s revenue for fiscal 2025 (year ended December 2025) was $81.4 million, up 14.9% from fiscal 2024.

Revenue
+2.17%
EPS
+78.0%
Free cash flow
+51.0%
Total debt
+1.87%

Quarter to June 2026, against a year earlier

1.66 0.06 −3.49%
Market cap
$209.4M
P/E
0.0×
Fwd P/E
−2.0×
Dividend yield
—
F-score
5/9
Altman Z
−6.67
Beneish M
−2.09
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

3 5 3 2
ROE
81.41% 73.43% 60.27% 45.35%
ROA
(52.26%) (44.22%) (48.57%) (32.25%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(74.16%) (60.39%) (65.50%) (55.26%)
Average Days of Receivables
111.22 130.63 143.12 128.58
Free Cash Flow per Share
(0.97) (1.11) (0.74) (0.66)
Free Cash Flow
(132.26) (140.78) (113.92) (101.64)
Other line items

Show all line items

Columns are period end dates